SCHEMBL3219494

SCHEMBL3219494

CCN(CC)c1ccc(-n2nc3ccc(NC(=O)c4ccc(Cl)cc4)cc3n2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.59
THRB P10828 2/20 0.59
RXFP1 Q9HBX9 2/20 0.57
TP53 P04637 3/20 0.55
KDM4E B2RXH2 2/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
ALDH1A1 P00352 2/20 0.52
LMNA P02545 2/20 0.52
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
MAPK1 P28482 2/20 0.50
RORC P51449 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
NR4A1 P22736 1/20 0.50
GAA P10253 1/20 0.50
HPGD P15428 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3224129 0.91 MAPT (0.55) MAPTTHRBRXFP1TP53KDM4E
SCHEMBL3210188 0.89 MAPT (0.60) MAPTTHRBRXFP1TP53KDM4E
SCHEMBL3224063 0.88 MAPT (0.53) MAPTTHRBTP53KDM4EMEN1
SCHEMBL3229058 0.88 NPC1 (0.63) MAPTTHRBRXFP1TP53KDM4E
SCHEMBL3227976 0.83 NPC1 (0.57) MAPTRXFP1TP53KDM4EMEN1
SCHEMBL3231516 0.83 MAPT (0.72) MAPTTP53KDM4EMEN1KMT2A
SCHEMBL3220600 0.82 NPC1 (0.72) MAPTTHRBRXFP1TP53KDM4E
SCHEMBL27738460 0.81 RAB9A (0.56) MAPTTP53KDM4EMEN1KMT2A
SCHEMBL3224286 0.81 MAPT (0.73) MAPTRXFP1TP53KDM4EMEN1
SCHEMBL3225797 0.81 NPC1 (0.71) MAPTRXFP1TP53KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100168072-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy BIOMARIN IGA LIMITED 2010-07-01 US claimed
US-20100168072-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy BIOMARIN IGA LIMITED 2010-07-01 US disclosed
US-20100048660-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY BIOMARIN IGA LIMITED (BS) 2010-02-25 US disclosed
CN-101420952-A Treatment of duchenne muscular dystrophy SUMMIT CORP PLC (GB) 2009-04-29 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100048660-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SMN1; SMN2, CPT1B, GYS1 MAPT 4772/4885THRB 1728/4885RXFP1 401/4885
US-20100168072-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy CPT1B, PYGM, MTPN MAPT 2870/4885THRB 679/4885RXFP1 1398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.